23:20 , Oct 2, 2017 |  BC Extra  |  Company News

Endocyte soars on deal for ABX's CRPC candidate

Endocyte Inc. (NASDAQ:ECYT) jumped $2.22 (157%) to $3.63 on Monday after ABX GmbH (Radeberg, Germany) granted the biotech exclusive, worldwide rights to develop and commercialize prostate-specific membrane antigen (PSMA; FOLH1; GCPII)-targeting ligand PSMA-617. ABX received $12...
21:31 , Mar 21, 2017 |  BC Week In Review  |  Clinical News

Betalutin: Ph I LYMRIT 37-05 started

Nordic Nanovector began the open-label, dose-escalation, international Phase I LYMRIT 37-05 trial to evaluate injections of Betalutin in up to 24 patients who are ineligible for an autologous stem cell transplant (ASCT). Nordic Nanovector ASA (OSE:NANO),...
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
00:03 , Dec 8, 2016 |  BC Extra  |  Financial News

Nordic Nanovector prices private placement

Nordic Nanovector ASA (OSE:NANO) raised NOK498.7 million ($59.2 million) through the sale of 4.4 million shares at NOK114 in a private placement. DNB Markets, Jefferies and ABG Sundal Collier were underwriters. Nordic Nanovector intends to...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Nordic Nanovector, Wilex deal

Nordic Nanovector and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to develop antibody-drug conjugates (ADCs) to treat leukemia. Nordic Nanovector will provide an undisclosed antibody against leukemia cells, and Heidelberg Pharma will utilize its ADC technology...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Betalutin: Additional Phase I/II data

Data from 8 patients with relapsed CD37+ indolent B cell NHL in the open-label, dose-escalation, European Phase I/II LYMRIT-37-01 trial showed that pre-dosing with a 40 mg dose of unlabeled lilotomab prior to a single...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Betalutin: Phase I/II expanded

Nordic will expand the ongoing, open-label, dose-escalation, European Phase I/II LYMRIT-37-01 trial evaluating single injections of Betalutin to include a dose-finding portion. Previously, the dose-finding portion was to be conducted in parallel as a run-in...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

Betalutin: Preliminary Phase I/II data

Preliminary data from 11 evaluable patients with mantle cell lymphoma (MCL) or follicular lymphoma in the Phase I portion of an open-label, dose-escalation, European Phase I/II trial showed that single doses of 10, 15 and...
01:57 , Mar 21, 2015 |  BC Extra  |  Financial News

Nordic Nanovector raises NOK500M in IPO

Hematology and oncology play Nordic Nanovector ASA (OSE:NANO) raised NOK500 million ($60.9 million) in an IPO through the sale of 15.6 million shares at NOK32, giving it a market cap of NOK1.3 billion ($164.4 million)....
00:56 , Jun 19, 2014 |  BC Extra  |  Financial News

Nordic Nanovector raises $41.6 million

Nordic Nanovector A/S (Oslo, Norway) raised NOK250 million ($41.6 million) through the sale of 10 million shares at NOK25 in a private placement to existing shareholders and institutional investors. The company's largest shareholder, HealthCap, purchased...